News Hub | News Direct

All Industries


Article thumbnail News Release

PayMedix/TempoPay Names David Kinsey Vice President of Sales

PayMedix/TempoPay

PayMedix/TempoPay announced today the appointment of David Kinsey as Vice President of Sales. Kinsey joins during a period of accelerated growth for PayMedix/TempoPay, which delivers innovative healthcare payment solutions that provide interest-free financing to employees for healthcare services, no matter their credit histories. Kinsey brings an extensive background in the healthcare and employee benefits industry. In his new role, Kinsey will lead sales initiatives, focused on driving growth of the PayMedix/TempoPay solution and building strategic relationships across the healthcare industry with a specific focus on the Southeast region. “As more health systems, employers, and benefits administrators across the country continue to look for ways to lower costs and provide affordable access to healthcare for employees, we're seeing increased interest in our flexible financing and payments solutions," said Tom Policelli, CEO of PayMedix/TempoPay. "David's extensive knowledge of healthcare sales and the employee benefits industry will help us increase our reach and ability to serve providers and employers looking for alternative healthcare payment solutions. We are excited to welcome him to our team." Before his current role, Kinsey was an Executive Director at Aetna. He led the Healthcare Business Solutions team to achieve 60% growth over five years by directing enterprise sales, retention, and membership growth strategy. Kinsey was awarded Aetna's Chairman's Leadership Award for his leadership and collaboration. Kinsey’s prior roles at Aetna included working with employer groups and consultants on innovative employee benefits strategies and plan administration. Prior to Aetna, he was a Senior Client Manager at Cigna Healthcare, where he was awarded the Gold Circle for top sales results. He earned his BBA in Finance from Stetson University. "The PayMedix/TempoPay solution is a game-changer, offering a straightforward and effective approach to tackling the demanding issue of high out-of-pocket healthcare costs," said Kinsey. "I look forward to working with the team to expand our reach and bring employers a financial safety net for their employees that ultimately improves retention and reduces absenteeism.” “Having worked with David previously, I am confident in his ability to help employers, PEOs, health plans and network builders see the value in our solution,” said Brian Marsella, President, PayMedix/TempoPay. “By ensuring individuals have access to financial resources to get care when they need versus when they think they can afford it, we can break the cycle of care avoidance, which historically has led to sicker patients entering the system, worse outcomes and increased costs.” About PayMedix PayMedix, which began as the financing arm of Wisconsin-based HPS over a decade ago, is the only company solving the problem of high out-of-pocket costs for everyone -- providers, patients, employers, and TPAs. PayMedix is changing how people access, use, and pay for healthcare by guaranteeing payments to providers and financing for all patients. PayMedix has processed more than $5 billion in medical payments for hospital systems and physician practices and can be implemented in conjunction with any PPO or HMO network. About TempoPay TempoPay partners with employers to help their employees manage their medical costs with interest-free financing and flexible repayment options. With the TempoPay Visa® card employees can take control of how they pay for healthcare without added stress, providing simple access to the financial security needed for happier, healthier lives. Contact Details Brodeur Partners Sam LeCompte +1 603-660-9407 slecompte@brodeur.com Company Website https://paymedix.com

September 05, 2024 10:00 AM Eastern Daylight Time

Article thumbnail News Release

pSTAKE is expanding Bitcoin Liquid Staking on Babylon to BNB Chain

pSTAKE

pSTAKE Finance is proud to announce that it is expanding its Bitcoin Liquid Staking solution to BNB Chain users in the near future by: Bringing yBTC (pSTAKE-issued LST for Bitcoin) to BNB Chain Accepting BTCB deposits on BNB Chain This latest addition to the Bitcoin Liquid Staking solution marks a significant milestone in providing BNB Chain users with unique opportunities to generate yields through Bitcoin Staking. pSTAKE Announces Bitcoin Liquid Staking for BNB Chain Bitcoin Staking is bringing native yields to BTC for the first time. From a DeFi perspective, this can be a huge unlock for the entire industry, with $1.2T+ capital currently sitting idle. pSTAKE Finance’s Bitcoin liquid staking product allows BTC holders to stake native BTC and generate native staking yield through innovative protocols like Babylon. By turning BTC into a slashable asset, Babylon can utilize BTC to add economic security to PoS chains and earn rewards for BTC holders. pSTAKE Finance’s liquid staking solution went live on July 28, 2024, and it quickly filled its 50 BTC deposit cap in three weeks. It then deposited a portion of its BTC into Babylon’s Staking Cap 1, marking the beginning of yields to its BTC depositors through Babylon Points and pSats (pSTAKE Points). BNB Chain is one of the leading Layer 1 chains in crypto, at a unique intersection of Bitcoin and DeFi. It has $6.7B+ TVL across leading DeFi protocols like Venus Protocol, PancakeSwap, BounceBit, Avalon Finance, Radiant Capital, ListaDAO, Aave, and more. BNB Chain is also home to the second biggest wrapped Bitcoin token, with a $4B+ supply of BTCB, Binance-wrapped Bitcoin. In line with decentralization and growing accessibility for Bitcoin yields, pSTAKE Finance has announced that it will bring its upcoming BTC LST yBTC to the BNB Chain and support BTCB deposits in its Bitcoin Liquid Staking solution. This move will bring further Bitcoin liquidity to BNB Chain and propel its existing DeFi Ecosystem. Due to its yield-generating nature, DeFi protocols can leverage yBTC as a pristine collateral asset and offer additional yields to users. At the same time, BTCB holders can stake with pSTAKE directly to earn rewards by contributing to the security of PoS chains through Babylon. Significance of BTCB BTCB is a tokenized version of Bitcoin on the BNB Chain that allows BTC holders to access the BNB ecosystem. The wrapped version of Bitcoin is held at a 1:1 peg to ensure BTCB mirrors Bitcoin's value. The wrapped BTC variant is designed to help bridge the gap between Bitcoin and the BNB Chain DeFi ecosystem and access a wide range of services on the BNB Chain with fast transactions and low fees. BNB Chain takes a custodial approach to BTCB by managing its minting and burning. As a result, Binance, one of the world’s largest and most trusted exchanges, holds the equivalent amount of BTC in a multi-signature cold storage wallet. It also has a Binance Proof of collateral feature to check the Bitcoin held in reserve at any time. BTCB is already supported by various DeFi protocols, including Venus, Aave, Solv, and soon pSTAKE. Gala Wen, Director of Ecosystem Development at BNB Chain said: "BNB Chain’s mission is to bring Web3 to the next billion users, and we are excited to see pSTAKE expanding its Bitcoin liquid staking on Babylon to BTCB on BNB Chain. This expansion not only enhances DeFi opportunities for users but also brings us closer to our goal of making Web3 accessible.” Bitcoin Season 2 on BNB Chain with pSTAKE By bringing yBTC to BNB Chain, pSTAKE expands its offering to provide more accessibility and yields to Binance users, one of the most active userbases in the crypto space. pSTAKE’s integration with BTCB provides more value to BNB Chain users by allowing holders of BTCB to access Bitcoin Staking yields securely with a single click. Bitcoin has already seen widespread adoption in BNB Chain DeFi. In the future, a yield-generating Bitcoin token like yBTC will significantly boost DeFi. About pSTAKE Finance pSTAKE Finance is a Bitcoin Yield and liquid staking protocol, backed by Binance Labs. With pSTAKE Finance, users can liquid stake BTC to get rewards from Babylon's Trustless BTC staking for securing other app chains while maintaining their liquidity. Accessing Bitcoin yields should not be complex, risky, or unsafe. With four years of liquid staking expertise and expert-curated yield strategies, pSTAKE Finance helps individuals and institutions put their BTC to work in BTCfi. pSTAKE Finance has partnered with leading blockchain security firms, such as Halborn, Hexens, Oak Security, Immunefi, Forta, and more, to offer a secure liquid staking product suite. Contact Details Colin Landers colin@energentmedia.net Company Website https://pstake.finance/

September 05, 2024 09:00 AM Eastern Daylight Time

Article thumbnail News Release

Introducing Brick Media: A New Force in Media Management and Innovation

Full Scope PR

Brick Media announces its powerful entrance into the media landscape, asserting itself as a catalyst for transformation. With a bold vision for content innovation and unparalleled management expertise, Brick Media is set to redefine and lead the charge in shaping the future of media. As a full-service media management firm at the intersection of content strategy and business execution, Brick Media is committed to nurturing the growth and monetization of its clients' careers across the digital media landscape. With a multifaceted approach, the company aims to elevate brands and voices across sports, entertainment, and beyond. Drawing from over a decade of unparalleled success in sports and entertainment management, Aaron & André Eanes of A&A Management bring their strategic expertise and deep industry insights to position Brick Media as a transformative force in the media sector. Leading this ambitious venture alongside them is CEO of Brick Media, Maggie Clifton. Formerly with Blue Wire and Wasserman, Maggie brings a wealth of experience and a visionary outlook to the company. Under her guidance, a team of highly skilled media professionals will spearhead the optimization of innovative and compelling content. Together, they stand ready to redefine the boundaries of the industry, heralding a new era of influence. "We founded Brick Media with the strategic vision of being a vital resource in the media industry for those seeking to elevate their clients' success to new levels. When we helped with the launch of New Heights, it revealed a critical need for an independent partner adept at steering through the intricacies of advertising, ancillary revenue streams, digital creation, and social growth. Brick Media fulfills that role, offering expert guidance and the best-in-class resources to empower achieving maximum value." says Aaron & Andre Eanes of A&A Management Group. "Brick Media is here to support our partners’ media businesses via strategy, monetization, distribution, marketing, and all other opportunities for growth. We’ve been building quietly all year and are excited to finally launch publicly.” says CEO of Brick Media, Maggie Clifton. In a remarkable inaugural achievement, Aaron Eanes of A&A Management Group and Maggie Clifton of Brick Media led negotiations a ground-breaking deal between the leading podcast studio Wondery and the widely acclaimed show, "New Heights with Jason and Travis Kelce," alongside Andre Eanes of A&A Management Group and Jason Bernstein of Clarity Football. This marks the beginning of Brick Media's mission to forge impactful partnerships and deliver unparalleled growth across the digital media landscape. Brick Media is dedicated to pushing the boundaries of creativity and strategic content development. As the company continues to forge influential partnerships and manage transformative projects, Brick Media is poised to become a leader in the digital media ecosystem. About Brick Media Brick Media is a media management firm specializing in content strategy and business development. Dedicated to fostering client growth and monetization across diverse media landscapes, including sports, entertainment, and news, Brick Media is set to make its mark on the future of media. Contact Details Alessandra Chisolm alessandra@fullscopepr.com

September 05, 2024 09:00 AM Eastern Daylight Time

Article thumbnail News Release

The Technology Powering Aeva's (NYSE: AEVA) Vision For A Safer Autonomous Future And Why It Could Be Game-Changing

Benzinga

By Meg Flippin, Benzinga When it comes to autonomous driving, safety and accuracy are top of mind. For self-driving cars, trucks and trains to become ubiquitous on America’s roads, streets and railways, they must be extremely safe and reliable. The same goes for the robots that will someday deliver everything from food to medicine without human intervention. They have to be able to see everything around them and react in real time to avoid crashes. Technology advances and companies like Aeva Technologies (NYSE: AEVA) are making that a reality. Mountain View, California-based Aeva makes LiDAR sensors for use in vehicles, trucks and trains. The sensors act as eyes, providing 3D views of the surroundings. FMCW, The Technology Enabler For Highway Autonomy What takes Aeva’s sensors to the next level on the safety and reliability fronts is its Frequency Modulated Continuous Wave (FMCW) 4D LiDAR technology, which uses a low-power continuous laser beam to measure range and a fourth dimension of velocity at the same time. Aeva says FMCW unlocks new levels of safety and automation by instantaneously discriminating between moving and non-moving points and knowing the precise velocity of objects in motion. Instant velocity data gives real-time insight into how an object’s position is changing, giving the vehicle’s computer a more accurate picture to help plan its next move. But that’s not all. Aeva’s sensors also have advanced perception capabilities that deliver new features, which the company says are not possible with typical legacy LiDAR sensors, including Ultra resolution and vehicle localization. Ultra resolution provides a camera-like image of the world providing what Aeva Technologies says is up to 20 times the resolution of legacy time-of-flight LiDAR sensors. Image segmentation enables the detection of roadway markings, drivable regions, vegetation, road barriers and road hazards like tire fragments at up to twice the distance of conventional time-of-flight LiDAR sensors. Instant velocity data allows for confident detection and tracking of dynamic objects such as oncoming vehicles and other moving objects at distances up to 500 meters, reports Aeva. Meanwhile the technology’s Vehicle Localization features enable real-time vehicle motion estimation with six degrees of freedom, providing accurate vehicle positioning and navigation, which could be a substitute for other sensors, like IMU or GPS. That provides for safe autonomous navigation in common GPS-denied environments like tunnels and parking structures. Aeva says its FMCW technology provides autonomous vehicles with freedom from interference from sunlight and other LiDAR sensors, elimination of retroreflector blooming and ghosting from highly reflective objects like street signs and roadway markings, as well as a greater ability to see in weather conditions like dust, fog, rain and snow. Importantly, these benefits can allow automated vehicles to safely operate at highway speeds, a feat that has been sought after by major car manufacturers. Overcoming The Limitations With all that safety and technology packed into Aeva’s LiDAR sensors, Aeva is overcoming one of the biggest challenges of self-driving vehicles today: blindspots. Self-driving vehicle algorithms and conventional sensors can have difficulty when the weather is bad, lane markings are not clear or unexpected obstacles are in their way. That can lead to accidents and fatalities. Reacting in real-time is the goal and Aeva delivers that with its LiDAR sensors. The company’s FMCW LiDAR sensors can also enable self-driving cars and trucks to achieve highway speeds safely. It's something that has eluded the industry so far, with many self-driving vehicles achieving top speeds of 35 to 45 MPH. For the trucking industry to move to autonomous vehicles, it has to be able to sustain highway speeds safely. Achieving that can someday address the labor shortages the heavy truck industry faces. Finding drivers who want to spend most of their time on the road and away from family for three to four-week clips is harder to come by. Autonomous trucks that can run all day and all night can help fill that gap. It’s why Daimler Truck AG is using Aeva’s sensors in its Class 8 Freightliner Cascadia autonomous truck platform. Daimler Truck intends to integrate the LiDAR sensors directly into its production process, making it easy for customers to buy autonomous-ready trucks directly from its manufacturing plants. Daimler Truck said it chose Aeva’s LiDAR sensors because of its ability to provide enhanced safety and control. “Daimler Truck is committed to leading the industry’s advancement toward autonomous trucks. Selecting the right LiDAR technology is a crucial strategic decision to safely deploy autonomous trucks on the road,” said Joanna Buttler, Head of Global Autonomous Technology Group at Daimler Truck. “We are convinced that Aeva with its cutting-edge and reliable technology is the right production partner for LiDAR sensors and has the manufacturing capabilities to scale along with us.” The world is moving toward autonomous vehicles but for them to become ubiquitous safety can’t be a question. That’s where companies like Aeva Technologies come in. Its advanced next-generation LiDAR sensors can react in real-time, potentially taking autonomous driving to the next level. Learn more about Aeva Technologies Inc. by checking out its investors deck here. Featured photo by Chris Bair on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 05, 2024 08:55 AM Eastern Daylight Time

Image
Article thumbnail News Release

Prescribing The Future: How MangoRx Is Shaking Up Telemedicine With A Fresh Platform

Benzinga

By Anthony Termini, Benzinga Since Covid-19, telemedicine has been expanding significantly, with 44% of physicians using it at least weekly and 40% daily in the U.S. in 2023. The industry is seen by some as a new frontier for patient education and access to medicine and care. The DEA Opens The Digital Door To The Telemedicine Industry Before the pandemic, the primary way a patient would get a drug prescription was through an in-person visit with a doctor. The Drug Enforcement Agency (DEA) loosened those restrictions, allowing physicians to prescribe “controlled medications” over the phone and via video conference. That’s been good for companies in the direct-to-consumer telehealth industry. One of the players in this business is MangoRx or Mangoceuticals, Inc. (NASDAQ: MGRX), which develops a variety of men's health and wellness products and services. Working with Surescripts, which helps coordinate all the parties in the prescription process, MangoRx recently transitioned its telemedicine platform to a newly developed DEA-approved telemedicine operating system. The new system allows MangoRx’s third-party doctor network to prescribe and offer controlled substances. These include Prime Protocol by MangoRx, powered by Kyzatrex, an Oral Testosterone Replacement Therapy and other hormone replacement treatments. According to Jacob Cohen, CEO and co-founder of MangoRx, the company is dedicated to “revolutionizing patient care,” and the new system enhances patient management by “offering seamless doctor visits, prescription auto-refills, and overall health management.” MangoRx is joined in the telehealth space by companies like Hims & Hers Health (NYSE: HIMS), a San Francisco-based telehealth company; Maximus Tribe, a compound pharmaceuticals company that also offers coaching and is based in Santa Monica, California; and Nu Image Medical, a Tampa, Florida-based company that sells weight loss, hormone replacement, sexual health, and general wellness products. Cohen argues, however, that MangoRx is setting a new benchmark for excellence in telemedicine. The company believes that the steps it is taking create meaningful competitive advantages over other companies in the space. MangoRx’s Digital Leap Shortens Time To Market MangoRx, which currently offers therapy options for erectile dysfunction, hair growth and hormone replacement, intends to use the new operating system to roll out new weight loss treatment options. These include an oral dissolvable GLP-1 tablet that includes Semaglutide and Tirzepatide, the ingredients in some of the most popular prescription weight loss medicines. The company’s new operating system helps it accelerate the ability to introduce other new product lines, the first of which is the dissolvable tablet they have branded as Slim and Trim. This brand will help MangoRx capitalize on the significant demand for GLP-1 weight loss treatments for both men and women. MangoRx expects these products will be available to patients before the end of the third quarter and that this new addition will help it to substantially grow revenue moving forward. The company says its new operating system will enable it to respond quickly to market needs and marks an important milestone for MangoRx, representing a significant advancement in its capabilities. Amanda Hammer, COO of MangoRx, says that the company has a “commitment to regulatory compliance and innovation” and that the new operating system’s cutting-edge technology puts it in a position to continue “revolutionizing patient care in the telemedicine industry.” MangoRx notes that the system is fully HIPAA-compliant to ensure that all operations adhere to stringent regulatory standards. The new system includes robust security measures to protect patient data and maintain the highest levels of confidentiality. The system upgrade accompanies a redesigned website with an improved user interface to optimize the customer experience and enhance workflows. The combination creates real-time data tracking and seamless integration that enhance operational efficiency and improve patient engagement. Featured photo by LinkedIn Sales Solutions on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 05, 2024 08:50 AM Eastern Daylight Time

Image
Article thumbnail News Release

$10K Up For Grabs For The Top 100 Traders In BullRush’s Upcoming Trading Event

Benzinga

By James Blacker, Benzinga Think you’ve got what it takes to take home the prize? Sign up for BullRush’s Crypto, Forex and CFD trading competition here. Gamified trading platform BullRush is offering a unique opportunity for anyone interested in learning how to trade while making money. Starting from its September 9 launch, the company is running a fantasy trading game with a total prize pool of $10,000 to be awarded to the top 100 traders in the competition. The trading competition will feature any of the following assets: Crypto, Forex and CFDs. Whether you are an experienced or beginner trader, BullRush’s launch event could be your chance to level up your skills and potentially walk away with a cash prize. Master The Art Of Trading With BullRush BullRush's trading platform offers skill-based games, which, much like chess, require participants to master various tools and strategies to outwit their opponents and win. The upcoming tournament allows traders to practice new skills, strategies and ideas in a demo account without using real money. This focus on strategy and skill makes BullRush a suitable learning ground for traders of all experience levels. Fantasy trading in a demo account has many benefits, such as the ability to test and refine your trading strategies, experiment with different styles as well as try out different asset classes. Furthermore, with simulated trading, you can forward-test your strategy in real-time live markets. Trading psychology is a major factor that can be the difference between success and failure in the markets. With no money at stake, fantasy trading lets you practice without the emotional stress and burnouts associated with trading, helping you to develop discipline before you transition your strategies to real-money trading. BullRush Is More Than Just Trading BullRush is not just a trading platform – it's an interactive community where traders can learn, compete and grow together. In addition to the games and tournaments, BullRush also offers trading courses, tutorials and trading analysis. The platform aims to foster a strong community spirit, with traders able to connect, share strategies and learn from one another. Joining The BullRush Community To commemorate its launch on September 9, Bullrush is hosting a launch event, where the best 100 traders in the competition will share a prize pool of $10,000. This fantasy trading game is not just about winning money; it's also about learning to trade effectively while having fun in a dynamic, interactive environment. As the official launch of BullRush approaches, now is the perfect time to get involved. Whether you're looking to test your skills, learn new strategies or simply enjoy the thrill of the game, BullRush offers a unique trading experience. With a $10K prize pool up for grabs, there's never been a better time to join the BullRush community and see what you're capable of. Think you’ve got what it takes to take home the prize? Sign up for BullRush’s Crypto, Forex and CFD trading competition here. Featured photo courtesy of BullRush. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 05, 2024 08:45 AM Eastern Daylight Time

Image
Article thumbnail News Release

Telomir Pharmaceuticals (NASDAQ: TELO) Featured In Local ABC Exclusive Showing Positive Outcomes Of Proposed Age Reversal Pill In Dogs

Benzinga

By Meg Flippin, Benzinga Turning back the clock on aging is a never-ending quest with people, large companies and startups pouring blood, sweat, tears – and tons of money – into finding a solution. One company that seems to be getting closer to its goal is Telomir Pharmaceuticals Inc. (NASDAQ: TELO), a pre-clinical pharma company seeking to lead developments in longevity science through treating age-related conditions. Its leading drug compound, Telomir-1, was featured in an ABC television news segment highlighting promising "age reversal" outcomes in a study with two senior dogs. Lengthening DNA’s Protective Caps Telomir-1, the company's leading drug compound, is designed to regenerate telomeres – the protective DNA structures at the ends of our chromosomes, often compared to the caps on shoelaces. Research has demonstrated that repairing these telomeres may extend biological age and reverse certain age-related conditions. By targeting telomere regeneration, Telomir-1 aims to slow down the aging process and combat diseases linked to telomere shortening. Telomir Pharmaceuticals says Telomir-1 is the first novel small molecule to lengthen the DNA’s protective telomere caps to potentially reverse age-related conditions. The novel molecule, which Telomir is testing with mice and dogs with an eye toward human clinical trials, binds to critical metals that wear down telomeres. By limiting the availability of metals and interrupting the enzyme function, Telomir-1 seeks to restore cellular metal homeostasis and reverse a person's or animal’s biological age. The oral therapy potentially provides what the company says is a safe and effective alternative to existing treatments with minimal side effects. Telomir-1 Gets Props In News Segment In the segment, "ABC7 Exclusive: New study reveals promising results for age reversal pill on dogs," the potential of Telomir-1 was on display through the stories of Zeus and Benson, two senior dogs from Donte's Den rescue organization in Myakka City, Florida. After being treated with Telomir-1, both dogs exhibited improvements in their health conditions, according to Telomir. Zeus, a 12-year-old German Shepherd, showed complete remission of terminal cancer, while Benson, a 12-year-old Newfoundland suffering from severe arthritis, regained his mobility, leading to what caretakers described as a miraculous recovery, reports Telomir. "The results of this study highlight the groundbreaking potential of Telomir-1. Our priority is to advance the rigorous scientific research required to bring this promising treatment to humans and pets through the regulatory process as swiftly and safely as possible," said Erez Aminov, CEO of Telomir. "At Telomir, we are dedicated to transforming the future of longevity science, and these early findings bring us one step closer to making that vision a reality." Aminov was named CEO earlier this month after the passing of Chairman of the Board and Chief Executive Officer Christopher Chapman, Jr., M.D. Aminov was most recently CEO of MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA). The positive preclinical trials have shown that Telomir-1 may have several applications in the veterinary market, which is large given that Americans are poised to spend $156 billion on their pets by the end of this year. The use of Telomir-1 in the two dogs was observed by Telomir's special advisor Dr. Michael Roizen, the former Chief Wellness Officer of the Cleveland Clinic and a leader in age-related medicine. In this small compassionate use program, remarkable improvements in the health and vitality of the dogs after treatment with Telomir-1 were noted, offering a glimpse into the potential future applications for humans, reported Telomir. "The preliminary results we're seeing with Telomir-1 are very encouraging. By lengthening telomeres, we believe Telomir-1 can promote cell regeneration and potentially reverse several aspects of aging or age-related conditions. I'm excited to continue working with Telomir to explore the full potential of this innovative therapy,” Roizen said. More Tests Underway Nobody wants to get old and that includes pets. With Americans pouring tons of money into keeping their pooches happy and healthy, they may someday have another tool: Telmoir-1. With encouraging results out of its study with two dogs and more positive results expected down the road, this may be a company worth paying attention to as the quest to reverse time continues. Featured photo by Simone Dalmeri on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 05, 2024 08:40 AM Eastern Daylight Time

Image
Article thumbnail News Release

Mainz Biomed (NASDAQ: MYNZ) And Liquid Biosciences Team Up To Fight Pancreatic Cancer With Early Detection Tool

Benzinga

By Meg Flippin, Benzinga Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, has inked a collaboration deal with Liquid Biosciences, an AI-focused bio-analytics company, to potentially add pancreatic cancer detection to its colorectal cancer screening test ColoAlert®. Liquid Biosciences leverages its EMERGE AI analysis technology platform to help biopharma companies, diagnostics industries and academic institutions identify effective drugs and therapies. Mainz Biomed is developing PancAlert, a screening test that combines genetic and potentially microbiome biomarkers to detect pancreatic cancer. Research has shown that the microbiome – the mix of bacteria in the gut – plays a big role in how tumors develop and progress. The constitution of the microbiome can potentially hurt the immune system’s ability to recognize and attack cancer and render drugs less effective. By combining DNA and microbiome biomarkers, Mainz is betting early detection of pancreatic cancer is possible. Promising Early Results In the initial phase of the collaboration, the companies evaluated biomarkers from Mainz’s research program, co-funded by the German government, by applying a single algorithm developed by Liquid Biosciences using its EMERGE platform. Mainz said the results of the feasibility analysis were promising, giving both companies confidence that PancAlert could be added to ColoAlert in the future. ColoAlert is an early detection screening that spots bleeding and non-bleeding tumors through tumor DNA analysis, offering what the company says is a better early detection than fecal occult blood tests. In the second phase of the collaboration, Mainz and Liquid Biosciences will expand the biomarker evaluation to include microbiome biomarkers Mainz evaluated in 2023 and an expansion of the algorithm. The companies are targeting to complete this analysis in the fourth quarter of 2024. “We are excited by the opportunity to collaborate with Liquid Biosciences on PancAlert, which is being developed for early-stage disease detection with the goal of being a first-in-class screening test for this deadly form of cancer,” said Guido Baechler, Chief Executive Officer of Mainz Biomed. “Liquid Biosciences is already a key partner in our Next Generation colorectal cancer screening test. Expanding our partnership will allow us to bring the power of AI to this critical problem.” Pancreatic Cancer Is Deadly And Growing Pancreatic cancer is a malignant neoplasm of the pancreas with one of the highest mortality rates of all major cancers. It is now the third-leading cause of cancer deaths, and by 2030 it is expected to grow to second place, surpassing colorectal cancer deaths. This year alone, about 66,440 Americans will be diagnosed with pancreatic cancer, a record for this deadly form of cancer. What’s more, about 51,750 Americans are expected to die from the disease this year. Among cancers, pancreatic disease is a tough one to treat. It’s a highly aggressive form of cancer that attacks the pancreas, an organ needed for digestion. With limited treatment options, the five-year survival rate is just 13%. It doesn’t help that most people are diagnosed with pancreatic cancer in a late stage when it has already spread to other parts of the body. That’s particularly true with pancreatic ductal adenocarcinoma (PDAC), which is a type of pancreatic cancer that’s created from the cells that line the ducts of the pancreas. It's one of the most lethal forms of pancreatic cancer. Given the difficulty in treating pancreatic cancer and the increasing incidents, a lot of medical research is directed toward earlier detection and better treatments. As a result, the global pancreatic cancer market is projected to reach $7.4 billion by 2032, growing at a CAGR of 13.7% over 2023-2032. Mainz’s collaboration with Liquid Biosciences is the latest in the company’s collaborations to bring its next-generation diagnostics technology to the masses. By combining biomarkers, Mainz is seeking to demonstrate a better and more effective way to spot deadly cancers that currently go undetected and untreated until it's too late. Featured photo by National Cancer Institute on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 05, 2024 08:35 AM Eastern Daylight Time

Image
Article thumbnail News Release

Crossroads Summit Taps Renowned Historian And Demographer Neil Howe As Panelist For November Event

Benzinga

By Anthony Termini, Benzinga The Crossroads Summit, scheduled to take place Nov. 21-22 in Miami, Florida, is billed as a conference for savvy investors and business leaders. Summit attendees will hear from visionaries in a number of disciplines, from academia to investment research. A central theme will be the role of rapid change in propelling innovations that create opportunity. Neil Howe: Navigating The Era Of Crisis And Renewal One of the visionaries recruited to speak at the Crossroads Summit is Neil Howe, an authority on generational trends. He is an economist and demographer, as well as a historian and sociologist. Howe is a senior associate at the Center for Strategic and International Studies and the Global Aging Institute, both in Washington, D.C. He is the Managing Director of Demography at Hedgeye Risk Management and his human resources and strategic planning consulting firm, LifeCourse Associates, has served hundreds of corporate, government and nonprofit clients. The author of several books on “generational theory”, which argues that history repeats itself in 80 to 100-year cycles, Howe will share his insights on how these turning points impact America's ability to invest in its future. In his latest book, “The Fourth Turning Is Here,” Howe shows that America is currently in the last stage of one of these long cycles. He describes past turnings as “traumatic and transformative” and notes that they “dramatically reshape attitudes, behaviors, and the future of society.” Howe will lead a fireside chat at the Crossroads Summit, sponsored by TradeStation Group, that will delve into what the current stage of these cyclical patterns implies for America’s present and future. Howe Among Many Experts To Speak At The Crossroads Summit More than a dozen speakers, all experts in their respective fields, will address attendees at the Crossroads Summit. Each will focus on how turmoil like what Howe identifies will inspire the innovative solutions that could drive future investment opportunities. The conference is intended to help investors learn how to adjust their investing strategies to focus on future themes such as the end of near-zero interest rates, immigration policy, changes in the domestic workforce and new investable products. Fireside chats and panel discussions are intended to offer attendees investable insights by uncovering the hidden trends and critical developments that are driving world markets and economies. TradeStation Group is the title sponsor of the Crossroads Summit. Ticket packages are available at the Crossroads Summit website. TradeStation Group’s Sponsorship In The Crossroads Summit The Crossroads Summit was created to help business leaders and investors cut through the current clutter of information. Today's leaders are often inundated with so much data that making future projections is more difficult than just a few years ago. Today’s world is facing unprecedented challenges and disruption with advancements in artificial intelligence, political and economic uncertainty, an increase in armed conflict and rapid changes in technologies like cryptocurrency and fintech innovations. The Crossroads Summit is intended to be a catalyst for uncovering investment opportunities. As such, it was a natural fit that a global financial services company like TradeStation Group should present the conference. TradeStation Group aims to offer investors comprehensive market access and high-quality trade execution. The platform provides trading capabilities in stocks, options, mutual funds, and ETFs. TradeStation Group’s sponsorship of the Summit appropriately dovetails its capabilities with the needs of attendees. See how the fourth turning might shape future investments by attending the 2024 Crossroads Summit. Featured photo by Holgi on Pixabay. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 05, 2024 08:30 AM Eastern Daylight Time

Image
1 ... 5859606162 ... 3764